Mark J. Ratain to Receptor, trkA
This is a "connection" page, showing publications Mark J. Ratain has written about Receptor, trkA.
Connection Strength
0.250
-
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
Score: 0.250